Skip to content
Screener

Amgen AMGN Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Pfizer logo
PfizerPFE
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$222.32B+43.3%
Enterprise value$279.05B+32.4%
P/E25.4×+2.0×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126
Line itemJune 30, 2026 / GrosscarryingamountsJune 30, 2026 / AccumulatedamortizationJune 30, 2026 / Other intangibleassets, netDecember 31, 2025 / GrosscarryingamountsDecember 31, 2025 / AccumulatedamortizationDecember 31, 2025 / Other intangibleassets, net
Developed-product-technology rights$47,793$(28,450)$19,343$47,805$(26,754)$21,051
Licensing rights3,902(3,573)3293,917(3,522)395
Research and development technology rights1,409(1,304)1051,425(1,305)120
Marketing-related rights1,202(1,202)1,203(1,203)
Total finite-lived intangible assets54,306(34,529)19,77754,350(32,784)21,566
Indefinite-lived intangible assets:
In-process research and development710710710710
Total other intangible assets$55,016$(34,529)$20,487$55,060$(32,784)$22,276

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's finite-lived intangible assets, accumulated amortization?
Amgen (AMGN) reported finite-lived intangible assets, accumulated amortization of $34.53B in Q2 2026.
How has Amgen's finite-lived intangible assets, accumulated amortization changed year-over-year?
Amgen's finite-lived intangible assets, accumulated amortization increased by 12.1% year-over-year, from $30.79B to $34.53B.
What is the long-term trend for Amgen's finite-lived intangible assets, accumulated amortization?
Over 5 years (2020 to 2025), Amgen's finite-lived intangible assets, accumulated amortization has grown at a 16.2% compound annual growth rate (CAGR), from $15.46B to $32.78B.
What does finite-lived intangible assets, accumulated amortization mean?
Finite-Lived Intangible Assets, Accumulated Amortization

Ask your AI about Amgen's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude